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The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrex-
ate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD)
prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT),
but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who under-
went RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic mye-
logenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling
(matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with
MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall sur-
vival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP,
MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute
GVHD (relative risk [RR], 1.78; P < .001) and grade III to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-
TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio,
1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among
the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on
GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute
GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, tar-
geting URD recipients are needed to confirm these results.










Although the development of reduced-intensity condi-
tioning (RIC) or nonmyeloablative conditioning has allowed
patients who are ineligible for myeloablative conditioning
(MAC) allogeneic hematopoietic cell transplantation
(alloHCT) to have access to this potentially curative ther-
apy, nonrelapse mortality (NRM) remains a significant
obstacle to its success [1]. The tight association between
graft-versus-host disease (GVHD) and NRM has led to
attempts to devise GVHD prevention strategies to decrease
its incidence and severity [2]. For the past 3 decades, the
regimen pioneered by the Seattle group combining a calci-
neurin inhibitor (CNI) with methotrexate (MTX) has been
the most widely adopted for GVHD prevention [3]. Cyclo-
sporine (CYSP) in combination with a short course of MTX
has been widely used since the late 1980s [4,5]. In more
recent years, tacrolimus (TAC) has emerged as an alterna-
tive to CYSP for GVHD prophylaxis [6]. CYSP and TAC share
a final common pathway of inhibition of IL-2mediated T
cell expansion and cytotoxicity [7]. Randomized trials have
shown that post-transplantation TAC-MTX is associated
with decreased acute GVHD (aGVHD) compared with CYSP-
MTX in patients with a matched sibling donor (matched
related donor [MRD]) [8] or matched unrelated donor
(URD) in the myeloablative setting [9]. There are, however,
several caveats with the use of MTX, mainly delayed
hematopoietic engraftment, increased oral mucositis, and
gastrointestinal toxicity, as well as pulmonary and renal
toxicity[2,10-12]. In patients undergoing RIC alloHCT,
reducing procedure-related toxicities may be of critical
importance, as these patients usually have greater comor-
bidities[1]. Therefore, to reduce MTX-associated toxicities,
mycophenolate mofetil (MMF) has been investigated as a
replacement for MTX in RIC regimens in recent years [13].Currently, at most transplant centers, GVHD prophylaxis is
largely based on CNI (CYSP or TAC) in combination with short-
course MTX or MMF [14,15]. There is, however, significant var-
iability among centers in GVHD prophylaxis regimens used. In
RIC alloHCT, MMF is widely used instead of MTX in combina-
tion with a calcineurin inhibitor for GVHD prophylaxis[15],
given the advantages of earlier engraftment and less mucositis.
A recent Center for International Blood and Marrow Transplan-
tation Research (CIBMTR) analysis [16] demonstrated signifi-
cantly worse overall survival (OS), NRM, and aGVHD and
chronic GVHD (cGVHD) with MMF compared with MTX after
RIC alloHCT from unrelated donors (URD). With the 4 regimens
of MTX-CYSP, MMF-CYSP, MTX-TAC and MMF-TAC being used
frequently as the current standard to prevent GVHD after RIC
alloHCT, an important and unanswered question is whether 1
of them is superior to others in preventing GVHD. We aimed to
describe and evaluate the comparative efficacy of the 4 com-




The CIBMTR is a combined research program of the Medical College of
Wisconsin and the National Marrow Donor Program, which consists of a vol-
untary network of more than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and autologous transplan-
tations to a centralized statistical center. Observational studies conducted by
the CIBMTR are performed in compliance with all applicable federal regula-
tions pertaining to the protection of human research participants. Protected
health information issued in the performance of such research is collected
and maintained in the CIBMTR's capacity as a Public Health Authority under
the Health Insurance Portability and Accountability Act Privacy Rule.
Patients
The study population included adult patients with acute myelogenous
leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous
leukemia (CML), and myelodysplastic syndrome (MDS) who underwent a
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8/8- or 7/8-matched unrelated donor (HLA-A, -B, -C, -DRB1) [17] and received
a combination of CNI (CYSP or TAC) and either MTX or MMF for prophylaxis
against GVHD. Haploidentical related donor and cord blood transplants were
excluded. All patients received a peripheral blood graft. Patients receiving ex
vivo T cell depletion and bone marrow grafts were excluded given their small
numbers.
Study Endpoints
The primary objective of the study was to evaluate and compare the risks
of aGVHD, cGVHD, and overall mortality with each of the 4 GVHD prophylaxis
regimens in RIC alloHCT patients receiving peripheral blood graft. The pri-
mary endpoints of the study, therefore, were grade II to IV and III to IV
aGVHD, cGVHD, and OS. OS was defined as the time from alloHCT to death
from any cause or until last follow-up. Death from any cause was considered
an event. Surviving patients were censored at last follow-up. Secondary end-
points included absolute neutrophil count recovery, platelet recovery, dis-
ease-free survival (DFS), relapse and NRM. Patients were censored at
subsequent transplant or date of last follow up. DFS was defined as time from
alloHCT to either relapse/progression or death from any cause. Patients alive
were censored at the time of relapse/progression or last follow-up, whichever
came first. NRMwas defined as death from any cause in continuous remission
and was summarized by cumulative incidence estimate with relapse as com-
peting risk. Relapse was defined as molecular, cytogenetic, or morphologic
evidence of disease recurrence. Relapse was summarized by cumulative inci-
dence estimate with NRM as the competing risk. For relapse and NRM,
patients in continuous complete remission were censored at last follow-up.
aGVHD and cGVHD were defined by the standard criteria[18,19]. For GVHD,
death without the event was considered a competing risk. All patients
received RIC/nonmyeloablative conditioning, which was defined as total
body irradiation (TBI) 5 Gy (single dose) or 8 Gy (fractionated), or busulfan
(Bu) 8 mg/kg (orally) or 6.4 mg/kg (intravenously) or melphalan<150 mg/
m2 [20].
Statistical Analysis
This is a retrospective cohort study describing and comparing outcomes
after RIC alloHCT using MTX+CNI (TAC versus CYSP) versus MMF+CNI (TAC
versus CYSP) as GVHD prophylaxis. To understand the impact of prophylaxis
regimen on outcomes after alloHCT, the patient population was divided into
4 cohorts depending on CNI used and whether it was combined with MMF or
MTX: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. Furthermore, 2 sepa-
rate analyses were performed: 1 for the group with MRD and the other for
the URD group.
The outcomes studied were aGVHD (grade II to IV, grade III to IV) and
cGVHD, OS, DFS, relapse, and NRM. Categorical variables were summarized as
frequency counts and percentages and compared among GVHD prophylaxis
cohorts using the chi-square test. Continuous variables were summarized as the
median and range and compared using the Mann-Whitney test. Probabilities of
OS and DFS were calculated using Kaplan-Meier estimator and compared among
the cohorts using the log-rank test. Probabilities of NRM, relapse and cGVHD
were calculated by cumulative incidence function accounting for competing
risks. Comparisons of cumulative incidence across time cohorts were performed
via Gray's test. Multivariate Cox proportional hazards regression models for all
the endpoints (aGVHD, cGVHD, OS, DFS, relapse, NRM, graft failure) were used
to compare the treatment groups. The assumption of proportional hazards for
each factor in the Cox model was tested using time-dependent covariates. There
is no variable violating the proportional hazard assumption in this study. Step-
wise selection was used to identify significant covariates that influenced out-
comes to be included in the final model to get the adjusted treatment effects,
the variables we considered in the variable selection included patient-related
(age, sex, Karnofsky Performance Status [KPS], ethnicity, HCT-comorbidity index,
disease-related [disease, disease status at alloHCT], donor-related [donor age
(URD only), donor-recipient sex match and cytomegalovirus [CMV] match) and
transplantation-related (year of transplant, in vivo T cell depletion using antithy-
mocyte globulin [ATG] and use of TBI in the conditioning) variables. Statistical
significance of the main effects was tested with the .01 level accounting for mul-
tiple comparisons across the endpoints. Potential interactions between the main
effect (GVHD prophylaxis) and significant adjusting were tested, and there are
no significant interactions at .01 level. Adjusted survival curves and cumulative
incidence curves were generated stratified on the treatment groups and
weighted averages of covariate values using the pooled sample proportion as
the weight function. These adjusted curves represent likelihood of outcomes in
populations with similar prognostic factors. The following power analyses were
conducted for the main outcome grade II to IV aGVHD, given the current patient
and event number in each GVHD prophylaxis cohort of the 2 groups. For the
MRD group, to detect a hazard ratio (HR) of 1.5 in 1 of the 6 pairwise compari-
sons among treatments with significance level .05, the power ranges from 27%
to 53% with Bonferroni adjustment used to adjust the multiple comparisonproblem. On the other hand, for the URD group, to detect a hazard ratio of 1.5 in
1 of the 6 pairwise comparisons among treatments with significance level .05,
the power ranges from 51% to 90%.
RESULTS
Patient, Disease, and Transplantation Characteristics
In the MRD group (n = 690), patient, disease, and trans-
plantation characteristics showed important differences
(Table 1). The median age at alloHCT was as low as 53 years
in MTX-CYSP and as high as 61 years in MMF-TAC cohort (P
< .001). A significantly lower proportion of MTX-CYSP
cohort patients had KPS of <90% (19%), whereas TAC-based
cohorts had higher proportions of patients with KPS <90%
(45% to 52%; P < .001). D 9 6X XAML was the most common alloHCT
indication (48% to 69%) in the MRD cohorts, followed by
MDS (24% to 45%; P < .001). Donor-recipient CMV serostatus
proportions were heterogeneous; for example, 11% of MTX-
CYSP patients were donor-recipient seronegative, compared
with 19% to 25% in the other 3 cohorts (P < .001). The com-
bination of ATG with alkylator (Bu, melphalan [Mel]), nucle-
oside analog (fludarabine [Flu]), or TBI-based conditioning
regimen was used in approximately a quarter of all 4
cohorts of MRD group. While in the 2000 to 2004 period,
43% of MTX-CYSP and 50% of MMF-CYSP patients received
alloHCT, and in the most recent 2009 to 2013 period, 17%
and 29% of the respective CYSP cohorts had alloHCT. In con-
trast, 13% of MTX-TAC and 19% of MMF-TAC received
alloHCT in 2000 to 2004, and in the 2009 to 2013 period,
57% and 56% patients in the respective TAC cohorts under-
went alloHCT (P < .001). The median follow-up of survivors
ranged from 48 to 59 months in the MRD cohorts.
In the URD group (n = 874), pretransplant variables were
similar among the 4 cohorts, with some exceptions
(Table 2). AML (54% to 60%) and MDS (26% to 35%) were
the 2 most common indications for alloHCT in the URD
group (P = .003). In the URD group, 70% to 85% patients in
the 4 cohorts were fully matched (8/8-) and 15% to 30%
were matched at 7/8 loci with their donors (P = .001). ATG
was used in 41% of each of the 2 MMF cohorts, but at a
higher frequency in the MTX cohorts (62% of MTX-CYSP
and 54% of MTX-TAC cohorts) of the URD group (P < .001).
The median follow-up of survivors ranged from 49 to 61
months in the URD cohorts. In the earliest period of 2000
to 2004, 17% and 18% of MTX-CYSP and MMF-CYSP cohorts
and 4% and 11% of MTX-TAC and MMF-TAC cohorts, respec-
tively, received alloHCT (P < .001). The proportions of
alloHCT recipients in the most recent 2009 to 2014 were
28% and 38% in the CYSP cohorts and 58% and 43% in the
TAC cohorts, respectively.
Acute GVHD
Univariate analysis demonstrated that in the MRD group,
the cumulative incidences of grade II to IV aGVHD at day 100
post-transplant were 27% (95% CI, 21% to 33%) in the MTX-
CYSP cohort and 39% (95% CI, 30% to 48%) in the MMF-CYSP
cohort (Table 3). In the MTX-TAC and MMF-TAC cohorts of the
MRD group, however, the incidences were 21% (95% CI, 17% to
26%) and 29% (95% CI, 18% to 40%), respectively. Univariate
analysis also showed that the cumulative incidences of grade
III to IV aGVHD at day 100 were 8% (95% CI, 5% to 12%), 18%
(95% CI, 12% to 26%), 8% (95% CI, 5% to 11%), and 14% (95% CI,
7% to 24%) in the MTX-CYSP, MMF-CYSP, MTX-TAC, and MMF-
TAC cohorts of the MRD group, respectively (Table 3). Multi-
variate analysis did not show any significant difference in the
Table 1
Characteristics of adult patients receiving their first RIC alloHCT for AML, ALL, CML, and MDS with a peripheral blood stem cell graft from an MRD and treated with
TAC/CYSP +MTX/MMF § ATG from 2000 to 2013
MTX-CYSP MMF-CYSP MTX-TAC MMF-TAC P Value
Patients 220 110 296 64
Centers 49 30 58 23
Patient related
Age at transplant, yr 53 (20-71) 58 (20-76) 60 (19-77) 61 (19-73) <.001*
Age at transplant <.001*
18-29 yr 10 (5) 3 (3) 5 (2) 4 (6)
30-39 yr 34 (15) 4 (4) 14 (5) 3 (5)
40-49 yr 42 (19) 13 (12) 26 (9) 3 (5)
50-64 yr 108 (49) 59 (54) 184 (62) 37 (58)
65+ yr 26 (12) 31 (28) 67 (23) 17 (27)
Ethnicity <.001*
Caucasian 120 (54) 94 (85) 264 (89) 57 (89)
Non-Caucasian 72 (33) 9 (8) 26 (9) 7 (11)
Sorror comorbidity index <.001*
before 2007 170 (77) 68 (61) 93 (31) 21 (33)
0-1 25 (11) 17 (15) 87 (29) 10 (16)
2+ 20 (9) 24 (22) 113 (38) 33 (52)
KPS <.001*
<90 43 (19) 40 (36) 154 (52) 29 (45)
90 171 (78) 69 (63) 138 (47) 35 (55)
Disease related
Disease <.001*
AML 111 (50) 55 (50) 203 (69) 31 (48)
ALL 15 (6) 10 (9) 8 (3) 3 (5)
CML 43 (20) 8 (7) 11 (4) 1 (2)
MDS 52 (24) 37 (34) 74 (25) 29 (45)
Disease status at transplant* <.001*
Early 109 (50) 62 (56) 189 (64) 37 (58)
Intermediate 64 (29) 14 (13) 40 (14) 8 (13)
Advanced 44 (20) 29 (26) 57 (19) 17 (27)
Donor related
Donor-recipient gender match .11
M/M 70 (32) 35 (32) 92 (31) 28 (44)
M/F 64 (29) 25 (22) 59 (20) 10 (16)
F/M 42 (19) 28 (25) 85 (29) 15 (23)
F/F 44 (20) 23 (21) 60 (20) 11 (17)
Donor-recipient CMV status <.001*
+/+ 138 (63) 42 (38) 124 (42) 30 (47)
+/ 25 (11) 13 (12) 30 (10) 5 (8)
/+ 27 (12) 27 (25) 78 (26) 15 (23)
/ 24 (11) 28 (25) 56 (19) 14 (22)
Transplant related
Conditioning regimen and ATG <.001*
Bu + Flu § others 69 (31) 18 (16) 149 (50) 18 (28)
Flu +Mel § others 72 (33) 36 (33) 69 (23) 18 (28)
TBI § Cy § Flu § others 26 (12) 30 (27) 17 (6) 12 (19)
ATG § Bu § Flu § others 50 (23) 11 (10) 60 (20) 15 (23)
ATG § TBI § others 3 (1) 15 (14) 1 (<1) 1 (2)
Year of transplant <.001*
2000-2004 110 (50) 47 (43) 39 (13) 12 (19)
2005-2008 73 (33) 31 (28) 88 (30) 16 (25)
2009-2013 37 (17) 32 (29) 169 (57) 36 (56)
Follow-up of survivors, mo 54 (2-138) 59 (3-166) 56 (3-154) 48 (23-124)
Values are n, median (range), or n (%).
M indicates male; F, female.
* statistical significance.
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aGVHD among the 4 cohorts in the MRD group (Table 4,
Figure 1A).
The URD cohorts had a higher cumulative incidence of
grade II to IV aGVHD on day 100 post-alloHCT on univariate
analysis: 32% (95%CI, 22% to 45%) and 53% (95% CI, 45% to
61%) in the MTX-CYSP and MMF-CYSP cohorts, respectively,
and 37% (95% CI, 32% to 41%) and 47% (95% CI, 41% to 54%)
using MTX-TAC and MMF-TAC, respectively (Table 5). The
cumulative incidences of grade III to IV aGVHD at day 100
were 15% (95% CI, 8% to 25%), 21% (95% CI, 15% to 28%), 13%(95% CI, 10% to 17%), and 21% (95% CI, 16% to 27%) in the MTX-
CYSP, MMF-CYSP, MTX-TAC, and MMF-TAC cohorts of the
URD group on univariate analysis, respectively (Table 5). Mul-
tivariate analysis of the URD group demonstrated that MMF-
CYSP resulted in increased incidence of grade II to IV aGVHD
compared with MTX-TAC (HR, 1.78; P < .001) (Table 6,
Figure 1B) and MTX-CYSP (HR, 2.23; P < .001) (not shown in
Table 6). A significantly higher incidence of grade III to IV
aGVHD was shown in the URD group with the GVHD prophy-
laxis of MMF-CYSP compared with MTX-TAC (HR, 1.93;
P = .006) (Table 6).
Table 2
Characteristics of adult patients receiving their first RIC alloHCT for AML, ALL, CML, and MDS from a URD with a peripheral blood stem cell graft and treated with CNI
(CYSP/TAC) +MTX/MMF + ATG from 2000 to 2013
MTX-CYSP MMF-CYSP MTX-TAC MMF-TAC P Value
Patients 71 153 432 218
Centers 26 35 68 39
Patient related
Age at transplant, yr 59 (23-74) 62 (21-76) 61 (18-76) 60 (20-79) .08
Age at transplant .16
18-29 yr 3 (4) 9 (6) 18 (4) 8 (3)
30-39 yr 4 (6) 7 (5) 23 (5) 20 (9)
40-49 yr 9 (13) 12 (8) 36 (8) 23 (11)
50-64 yr 40 (56) 67 (44) 226 (52) 113 (52)
65+ yr 15 (21) 58 (38) 131 (30) 54 (25)
Ethnicity <.001*
Caucasian 60 (85) 138 (90) 410 (95) 204 (93)
Non-Caucasian 6 (8) 10 (7) 21 (5) 12 (6)
Missing 5 (7) 5 (3) 1 (<1) 2 (<1)
Sorror comorbidity index <.001*
before 2007 46 (65) 75 (49) 129 (30) 98 (45)
0-1 14 (20) 29 (19) 108 (25) 40 (18)
2+ 10 (14) 42 (27) 188 (43) 75 (34)
Missing 1 (1) 7 (5) 7 (2) 5 (2)
KPS at transplant .07
<90 20 (28) 56 (37) 196 (45) 100 (46)
90 47 (66) 93 (61) 223 (52) 112 (51)
Missing 5 (6) 4 (3) 13 (3) 6 (3)
Disease related
Disease .003*
AML 39 (55) 92 (60) 248 (57) 120 (55)
ALL 3 (4) 12 (8) 9 (2) 15 (7)
CML 9 (13) 9 (6) 23 (6) 7 (3)
MDS 20 (28) 40 (26) 152 (35) 76 (35)
Disease status at transplant* .39
Early 40 (56) 95 (62) 255 (59) 125 (57)
Intermediate 9 (13) 16 (10) 71 (16) 33 (14)
Advanced 19 (26) 40 (26) 97 (22) 52 (24)
Missing 3 (4) 2 (1) 9 (2) 10 (5)
Donor-related
Donor type .001*
Unrelated, 8/8-matched 50 (70) 120 (78) 369 (85) 163 (75)
Unrelated, 7/8-matched 21 (30) 33 (22) 63 (15) 55 (25)
Unrelated donor age at transplant, yr 33 (20-60) 32 (20-56) 31 (18-61) 33 (18-60) .25
Unrelated donor age at transplant .27
18-29 yr 34 (49) 75 (49) 235 (54) 106 (49)
30-49 yr 25 (35) 66 (43) 152 (35) 94 (43)
50-60 yr 6 (8) 8 (5) 27 (6) 9 (4)
Missing 6 (8) 4 (3) 18 (4) 9 (4)
Donor-recipient sex match .06
M/M 25 (35) 56 (37) 201 (47) 83 (38)
M/F 25 (35) 39 (25) 121 (28) 58 (27)
F/M 9 (13) 32 (21) 54 (13) 35 (16)
F/F 12 (17) 26 (17) 56 (13) 42 (19)
Donor-recipient CMV status .82
+/+ 12 (17) 42 (27) 102 (24) 50 (23)
+/ 6 (8) 16 (10) 43 (10) 16 (7)
/+ 30 (42) 52 (34) 175 (41) 89 (41)
/ 22 (31) 38 (25) 101 (23) 57 (26)
Missing 1 (1) 5 (3) 12 (3) 6 (3)
Transplant related
Conditioning regimen and ATG <.001*
Bu + Flu § others 11 (15) 13 (9) 121 (28) 30 (14)
Flu +Mel § others 13 (18) 20 (13) 67 (16) 48 (22)
TBI § Cy § Flu § others 3 (4) 57 (37) 9 (2) 49 (22)
ATG § Bu § Flu § others 41 (58) 52 (34) 235 (54) 88 (40)
ATG § TBI § others 3 (4) 11 (7) 0 (0) 3 (1)
Year of transplant <.001*
2000-2004 12 (17) 28 (18) 17 (4) 24 (11)
2005-2008 39 (55) 67 (44) 164 (38) 100 (46)
2009-2013 20 (28) 58 (38) 251 (58) 94 (43)
Follow-up of survivors, mo 60 (4-120) 71 (16-191) 48 (5-126) 61 (12-146)
Values are n, median (range), or n (%).
* statistical significance.
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The 1-year cumulative incidences of cGVHD with MTX-
CYSP, MMF-CYSP, MTX-TAC, and MMF-TAC were 49% (95% CI,
42% to 56%), 39% (95% CI, 29% to 49%), 34% (95% CI, 29% to 40%),
and 34% (95% CI, 23% to 46%), respectively, on univariate analy-
sis of the MRD group (Table 3). Multivariate analysis did not
reveal any significant difference in the incidence of cGVHD
among the 4 cohorts in MRD group (Table 4, Figure 2A). In this
group, the addition of ATG to Flu/Bu conditioning was associ-
ated with lower cGVHD incidence (HR, .55; P = .001).
Univariate analysis demonstrated 1-year cumulative inci-
dences of cGVHD with MTX-CYSP, MMF-CYSP, MTX-TAC, and
MMF-TAC of 36% (95% CI, 25% to 47%), 50% (95% CI, 42% to
58%), 40% (95% CI, 35% to 45%), and 44% (95% CI, 37% to 50%),






Outcomes Probability (95% CI) (%) Probability (95% CI) (%)
aGVHD II-IV
1 mo 14 (9-19) 20 (13-28)
2 mo 21 (15-26) 33 (25-42)
100 d 27 (21-33) 39 (30-48)
aGVHD III-IV
1 mo 2 (1-5) 11 (6-18)
2 mo 6 (3-9) 16 (9-23)
100 d 8 (5-12) 18 (12-26)
cGVHD
100 d 6 (3-10) 3 (1-7)
6 mo 30 (24-37) 26 (18-35)
1 yr 49 (42-56) 39 (29-49)
OS
100 d 91 (87-94) 87 (80-93)
6 mo 80 (75-85) 75 (67-83)
1 yr 67 (61-74) 57 (48-66)
2 yr 59 (52-66) 46 (37-56)
DFS
100-d 82 (76-87) 76 (67-83)
6 mo 68 (61-74) 61 (51-70)
1 yr 57 (50-64) 46 (37-56)
2 yr 50 (43-57) 41 (32-50)
Relapse
100 d 10 (6-14) 17 (10-24)
6 mo 18 (13-23) 26 (18-35)
1 yr 24 (19-30) 34 (25-43)
2 yr 28 (22-35) 36 (27-46)
NRM
100-d 9 (5-13) 7 (3-13)
6 mo 15 (10-20) 13 (7-20)
1 yr 19 (14-24) 20 (13-28)
2 yr 21 (16-27) 23 (15-32)
GRFS
100 d 71 (64-77) 61 (52-70)
6 mo 39 (32-46) 35 (26-44)
1 yr 16 (11-22) 16 (9-24)
2 yr 13 (9-18) 13 (7-20)
CRFS
100 d 79 (73-84) 75 (67-83)
6 mo 56 (49-62) 49 (39-58)
1 yr 40 (33-47) 30 (22-40)
2 yr 35 (29-42) 27 (19-36)
Neutrophil recovery
14 d 36 (30-43) 38 (29-47)
28 d 93 (89-96) 91 (84-96)
Platelet recovery
14 d 14 (9-19) 29 (20-39)
28 d 78 (71-83) 84 (75-91)
CRFS indicates D1X Xchronic GVHD- and relapse-free survival.
*statistical significance.significant difference in the incidence of cGVHD among the 4
URD cohorts on multivariate analysis (Table 6, Figure 2B).
Overall Survival
The MRD cohort exhibited 2-year OS of 59% (95% CI, 52% to
66%) in the MTX-CYSP cohort, 46% (95% CI, 37% to 56%) in the
MMF-CYSP cohort, 48% (95% CI, 42% to 54%) in the MTX-TAC
cohort and 47% (95% CI, 35% to 59%) in the MMF-TAC cohort,
on univariate analysis (Table 3). Multivariate analysis was
unrevealing for a statistically significant difference among the
4 MRD cohorts (Table 4, Figure 3A).
The unadjusted probabilities of 2-year OS were 40% (95% CI,
28% to 52%), 45% (95% CI, 37% to 53%), 47% (95% CI, 42% to 51%)
and 41% (95% CI, 35% to 48%) in the MTX-CYSP, MMF-CYSP,




Probability (95% CI) (%) Probability (95% CI) (%) P Value
7 (4-10) 21 (12-32) <.001
15 (11-20) 24 (14-35) .003
21 (17-26) 29 (18-40) .01
2 (1-4) 14 (7-24) .02
6 (4-9) 14 (7-24) .03
8 (5-11) 14 (7-24) .04
2 (1-4) 3 (0-9) .24
18 (13-22) 18 (9-28) .01
34 (29-40) 34 (23-46) .01
93 (90-96) 83 (73-91) .08
78 (73-83) 69 (57-79) .31
60 (54-66) 55 (42-67) .13
48 (42-54) 47 (35-59) .05
76 (71-81) 71 (60-82) .22
61 (55-66) 54 (42-66) .17
50 (45-56) 48 (35-60) .22
41 (36-47) 44 (32-57) .21
21 (16-25) 14 (7-24) .005
32 (27-38) 32 (21-44) <.001
37 (31-43) 33 (22-46) .007
43 (37-48) 33 (22-46) .01
3 (2-6) 14 (7-24) .04
7 (4-10) 14 (7-24) .02
13 (9-17) 19 (10-30) .15
16 (12-21) 22 (13-33) .29
69 (63-74) 64 (52-75) .36
42 (37-48) 39 (27-51) .53
22 (18-27) 23 (13-34) .23
15 (11-19) 13 (6-22) .94
74 (69-79) 70 (59-81) .49
53 (47-58) 50 (37-62) .67
39 (34-45) 40 (28-52) .35
31 (25-36) 34 (23-46) .52
35 (30-41) 57 (45-69) .02
96 (94-98) 98 (92-100) .07
20 (15-25) 22 (13-34) .02
82 (77-87) 93 (85-98) .01
Table 4
Multivariate analyses in MRD RIC alloHCT
n (%) Estimate (95% CI) P Value
Grade II-IV aGVHD
GVHD prophylaxis .14
MTX-TAC (reference) 290 (43) 1.0
MMF-CYSP 109 (16) 1.6 (1.1-2.4) .02
MTX-CYSP 213 (32) 1.3 (.9-1.8) .17
MMF-TAC 63 (9) 1.2 (.7-2.0) .44
Conditioning regimen / ATG <.001*
BU+FLU § others (reference) 248 (37) 1.00
ATG § BU § FLU § others 134 (20) .9 (.4-1.1) .10
FLU+LPAM § others 193 (29) 1.7 (1.2-2.4) .001*
TBI § CY § FLU § others 100 (15) 1.2 (.8-1.9) .31
KPS .04*
<90 (reference) 258 (38) 1.0
90-100 404 (60) .7 (.5-.9) .01
Missing 13 (2) .8 (.2-2.5) .69
Grade III-IV aGVHD
GVHD prophylaxis .26
MTX-TAC (reference) 291 (43) 1.0
MMF-CYSP 109 (16) 1.6 (.9-2.8) .15
MTX-CYSP 213 (31) .9 (.5-1.6) .76
MMF-TAC 63 (9) 1.5 (.8-3.1) .23
Conditioning regimen / ATG .03*
Bu+Flu § others (reference) 248 (37) 1.0
ATG § Bu § Flu § others 134 (20) .6 (.3-1.3) .25
Flu+Mel § others 193 (29) 1.7 (1.0-2.8) .04
TBI § Cy § Flu § others 101 (15) 1.2 (.6-2.4) .53
cGVHD
GVHD prophylaxis .42
MTX-TAC (reference) 287 (43) 1.0
MMF-CYSP 103 (15) 1.1 (.7-1.7) .58
MTX-CYSP 210 (32) 1.3 (.9-1.8) .13
MMF-TAC 63 (9) 1.3 (.8-2.0) .25
Conditioning regimen / ATG .006*
Bu+Flu § others (reference) 246 (37) 1.0
ATG § Bu § Flu § others 134 (20) .5 (.4-.8) .001*
Flu+Mel § others 186 (28) 1.0 (.7-1.4) .95
TBI § Cy § Flu § others 97 (15) 1.1 (.7-1.7) .66
Disease status .04*
Early (reference) 385 (58) 1.0
Advanced 142 (21) 1.1 (.8-1.4) .74
Intermediate 117 (18) 1.2 (.8-1.6) .37
Missing 19 (3) 2.5 (1.3-4.7) .005*
Donor-recipient CMV match .02*
/ (reference) 113 (17) 1.0
+/+ 321 (48) 1.1 (.7-1.5) .74
+/ 71 (11) .6 (.4-1.0) .05
/+ 144 (22) .7 (.5-1.1) .11
Missing 14 (2) 1.8 (.7-4.5) .22
Donor-recipient sex match .01*
M-M (reference) 219 (33) 1.0
F-F 131 (20) 1.4 (1.0-2.0) .06
F-M 161 (24) 1.7 (1.2-2.4) .002*
M-F 152 (23) 1.5 (1.1-2.0) .02
Ethnicity .005*
Caucasian (reference) 512 (77) 1.0
Missing 43 (6) .9 (.5-1.6) .78
Non-Caucasian 108 (16) 1.7 (1.2-2.4) .001*
OS
GVHD prophylaxis .69
MTX-TAC (reference) 296 (43) 1.0
MMF-CYSP 110 (16) 1.2 (.9-1.5) .26
MTX-CYSP 220 (32) 1.0 (.8-1.3) .77
MMF-TAC 64 (9) 1.1 (.8-1.6) .52
Age at transplant .002*
18-29 yr (reference) 22 (3) 1.0
30-39 yr 55 (8) 1.6 (.6-4.0) .35
40-49 yr 84 (12) 1.9 (.8-4.7) .13
50-64 yr 388 (56) 2.8 (1.2-6.4) .01
(continued)
65+ yr 141 (20) 3.3 (1.4-7.7) .006*
Disease .008*
AML (reference) 400 (58) 1.0
ALL 35 (5) 1.3 (.8-2.0) .28
CML 63 (9) .6 (.3-1.0) .05
MDS 192 (28) .7 (.6-.9) .02
Disease status .01*
Early (reference) 397 (57) 1.0
Advanced 147 (21) 1.4 (1.1-1.8) .004*
Intermediate 126 (18) .D2X X9 (.6-1.2) .50
Missing 20 (3) 1.5D3X X(.8-2.7) .16
KPS .006*
<90 (reference) 264 (38) 1.0
90-100 413 (60) .7 (.6-.8) .002*
Missing 13 (2) 1.1 (.6-2.2) .78
DFS
GVHD prophylaxis .22
MTX-TAC (reference) 287 (43) 1.0
MMF-CYSP 108 (16) 1.1 (.9-1.5) .29
MTX-CYSP 212 (32) .8 (.7-1.1) .19
MMF-TAC 63 (9) 1.1 (.8-1.5) .71
Disease status .003*
Early (reference) 390 (58) 1.0
Advanced 146 (22) 1.4 (1.1-1.8) .002*
Intermediate 116 (17) .9 (.7-1.2) .55
Missing 18 (3) 1.6 (.9-2.7) .08
Donor-recipient CMV match .006*
/ (reference) 118 (18) 1.0
+/+ 325 (48) 1.1 (.9-1.5) .38
+/ 69 (10) 1.3 (.9-1.8) .20
/+ 144 (21) 1.2 (.9-1.7) .20
Missing 14 (2) 3.1 (1.7-5.6) <.001*
KPS .01*
<90 (reference) 259 (39) 1.0
90-100 399 (60) .7 (.6-.9) .004*
Missing 12 (2) 1.0 (.5-2.1) .97
NRM
GVHD prophylaxis .54
MTX-TAC (reference) 287 (43) 1.0
MMF-CYSP 108 (16) 1.3 (.8-2.1) .23
MTX-CYSP 212 (32) 1.3 (.9-2.0) .19
MMF-TAC 63 (9) 1.2 (.7-2.1) .51
Conditioning regimen / ATG .02*
Bu+Flu § others (reference) 246 (37) 1.0
ATG § Bu § Flu § others 131 (20) 1.2 (.7-2.0) .47
Flu+Mel § others 188 (28) 1.9 (1.3-2.8) .002*
TBI § Cy § Flu § others 105 (16) 1.5 (.9-2.6) .10
Disease status .03*
Early (reference) 390 (58) 1.0
Advanced 146 (22) 1.2 (.8-1.7) .32
Intermediate 116 (17) .6 (.4-1.0) .07
Missing 18 (3) 2.2 (1.0-4.7) .04
Donor-recipient sex match .002*
M-M (reference) 219 (33) 1.0
F-F 135 (20) .9 (.6-1.5) .77
F-M 164 (24) 1.8 (1.2-2.7) .003*
M-F 152 (23) 1.0 (.6-1.6) .98
Sorror comorbidity index .03*
0-1 (reference) 134 (20) 1.0
2 187 (28) 2.3 (1.3-4.2) .003*
Missing 10 (1) 2.4 (.7-8.3) .18
N/A before 2007 339 (51) 2.0 (1.2-3.5) .01
Relapse
GVHD prophylaxis .22
MTX-TAC (reference) 287 (43) 1.0
MMF-CYSP 108 (16) 1.1 (.7-1.6) .70
MTX-CYSP 212 (32) .7 (.5-1.0) .07
MMF-TAC 63 (9) .9 (.6-1.5) .80
Conditioning regimen / ATG <.001*
Bu+Flu § others (reference) 246 (37) 1.0
ATG § Bu § Flu § others 131 (20) 1.1 (.8-1.5) .65
Flu+Mel § others 188 (28) .4 (.3-.6) <.001*
TBI § Cy § Flu § others 105 (16) .9 (.6-1.3) .55
Disease .03*
(continued)
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AML (reference) 393 (59) 1.0
ALL 34 (5) .9 (.5-1.8) .85
CML 59 (9) 1.0 (.6-1.7) .96
MDS 184 (27) .6 (.5-.8) .003*
Disease status <.001*
Early (reference) 390 (58) 1.0
Advanced 146 (22) 2.1 (1.5-2.8) <.001*
Intermediate 116 (17) 1.2 (.8-1.9) .28
Missing 18 (3) 1.9 (.9-4.2) .11
Donor-recipient CMV match .02*
/ (reference) 118 (18) 1.0
+/+ 325 (48) 1.2 (.9-1.8) .23
+/ 69 (10) 1.4 (.9-2.2) .15
/+ 144 (21) 1.3 (.9-1.9) .21
Missing 14 (2) 3.3 (1.6-6.7) <.001*
Sorror comorbidity index .003*
0-1 (reference) 134 (20) 1.0
2 187 (28) 1.0 (.7-1.4) .94
Missing 10 (1) .4 (.1-1.4) .18
N/A before 2007 339 (51) .6 (.4-.8) .001*
* statistical significance.
80 S. Chhabra et al. / Biol Blood Marrow Transplant 25 (2019) 7385respectively (Table 5). Multivariate analysis did not show any
significant difference among the cohorts of URD group (Table 6,
Figure 3B).
Disease-Free Survival
Univariate analysis demonstrated 2-year DFS of in the MRD
group of 50% (95% CI, 43% to 57%) in the MTX-CYSP cohort, 41%
(95% CI, 32% to 50%) in the MMF-CYSP cohort, 41% (95% CI, 36%
to 47%) with MTX-TAC, and 44% (95% CI, 32% to 57%) with
MMF-TAC (Table 3). There was no significant difference in DFS
among any of the GVHD cohorts in the MRD group on multi-
variate analysis (Table 4).
In the URD group, DFS at 2 years was 36% (95% CI, 25% to
48%) in the MTX-CYSP cohort, 41% (95% CI, 33% to 49%) in the
MMF-CYSP cohort, 38% (95% CI, 33% to 42%) in the MTX-TAC
cohort, and 33% (95% CI, 27% to 40%) in the MMF-TAC cohort
(Table 5). Multivariate analysis did not show any significant
difference in DFS among any of the URD cohorts (Table 6).
Relapse
Univariate analysis revealed that in the MRD group, the
cumulative incidences of relapse at 2 years were 28% (95% CI,Figure 1. (A) Adjusted curves for cumulative incidence of grade II-IV acute GVHD in M
MTX, CYSP-MTX, CYSP-MMF, and TAC-MMF. (B) Adjusted curves for cumulative incide
phylaxis regimens: TAC-MTX, CYSP-MTX, CYSP-MMF, and TAC-MMF.22% to 35%) and 36% (95% CI, 27% to 46%) in the MTX-CYSP and
MMF-CYSP cohorts, respectively, and 43% (95% CI, 37% to 48%)
and 33% (95% CI, 22% to 46%) in the MTX-TAC and MMF-TAC
cohorts, respectively (Table 3). The risk of relapse was not
shown to be significantly different among any of the 4 cohorts
in the MRD group on multivariate analysis (Table 4).
In the URD group, the 2-year cumulative incidences of
relapse were 34% (95% CI, 23% to 46%), 27% (95% CI, 21% to
35%), 40% (95% CI, 35% to 44%), and 31% (95% CI, 25% to 37%) in
the MTX-CYSP, MMF-CYSP, MTX-TAC, and MMF-TAC cohorts,
respectively, on univariate analysis (Table 5). On multivariate
analysis, URD patients receiving MMF-CYSP had a significantly
lower risk of relapse, compared with those receiving MTX-TAC
(HR, .53; P < .001) (Table 6).
Nonrelapse Mortality
On univariate analysis, the cumulative incidences of NRM at
2 years post-alloHCT in the MRD group were 21% (95% CI, 16%
to 27%), 23% (95% CI, 15% to 32%), 16% (95% CI, 12% to 21%), and
22% (95% CI, 13% to 33%) in the MTX-CYSP, MMF-CYSP,
MTX-TAC, and MMF-TAC cohorts, respectively (Table 3). Multi-
variate analysis did not show any significant difference in NRM
among the 4 GVHD cohorts of MRD group (Table 4).
The cumulative incidences of NRM at 2 years in the URD
group were 31% (95% CI, 20% to 43%), 31% (95% CI, 24% to 39%),
23% (95% CI, 19% to 27%), and 37% (95% CI, 31% to 43%) in the
MTX-CYSP, MMF-CYSP, MTX-TAC, and MMF-TAC cohorts,
respectively (Table 5). Multivariate analysis of the URD group
demonstrated that compared with MTX-TAC, MMF-TAC was
associated with increased risk of NRM (HR, 1.48; P = .008)
(Table 6), notwithstanding the faster neutrophil recovery
observed with MMF-TAC compared with other regimens (P <
.001) (Table 5).
DISCUSSION
The combinations of CNI with MTX or MMF for prevention
of aGVHD and cGVHD after alloHCT have been accepted as the
current standard,[6,8,9,18] although conflicting reports of out-
comes with MMF- and MTX-containing CNI-based regimens
have been noted. Despite the lack of prospective comparative
data between MMF- and MTX-based regimens in the RICRD recipients of RIC alloHCT using 1 of the 4 GVHD prophylaxis regimens: TAC-











Outcomes Probability (95% CI) (%) Probability (95%CI) (%) Probability (95% CI) (%) Probability (95% CI) (%) P Value
aGVHD II-IV
1 mo 15 (8-25) 38 (30-45) 18 (15-22) 26 (21-32) <.001
2 mo 31 (21-42) 51 (43-59) 33 (29-37) 41 (35-48) <.001
100 d 32 (22-44) 53 (45-61) 37 (32-41) 47 (41-54) <.001
aGVHD III-IV
1 mo 8 (3-16) 16 (10-22) 8 (6-11) 14 (10-19) .03
2 mo 15 (8-25) 21 (15-28) 12 (9-16) 19 (14-25) .02
100 d 15 (8-25) 21 (15-28) 13 (10-17) 21 (16-27) .06
cGVHD
100 d 3 (0-8) 10 (6-15) 4 (3-6) 2 (1-5) .03
6 mo 19 (10-29) 36 (28-43) 22 (18-26) 26 (21-33) .01
1 yr 36 (25-47) 50 (42-58) 40 (35-45) 44 (37-50) .11
OS
100 d 77 (67-86) 83 (77-89) 87 (83-90) 81 (75-86) .12
6 mo 66 (54-76) 69 (62-76) 78 (74-82) 67 (61-73) .006
1 yr 54 (42-66) 57 (49-65) 60 (55-65) 49 (42-56) .06
2 yr 40 (28-52) 45 (37-53) 47 (42-51) 41 (35-48) .49
DFS
100 d 72 (60-82) 73 (66-80) 74 (69-78) 70 (64-76) .78
6 mo 59 (47-71) 60 (52-68) 61 (57-66) 56 (49-62) .59
1 yr 50 (38-62) 50 (42-58) 48 (43-53) 41 (34-47) .21
2 yr 36 (25-48) 41 (33-49) 38 (33-42) 33 (27-40) .47
Relapse
100 d 16 (9-26) 15 (10-21) 17 (14-21) 15 (11-20) .85
6 mo 26 (16-37) 19 (13-26) 26 (22-31) 24 (18-30) .29
1 yr 30 (20-42) 23 (17-30) 35 (30-39) 28 (22-34) .03
2 yr 34 (23-46) 27 (21-35) 40 (35-44) 31 (25-37) .02
NRM
100 d 12 (5-21) 12 (7-17) 9 (6-12) 15 (10-20) .16
6 mo 15 (7-25) 21 (15-28) 13 (10-16) 21 (16-27) .02
1 yr 20 (11-30) 27 (20-34) 17 (14-21) 31 (25-37) <.001
2 yr 30 (19-42) 31 (24-39) 23 (19-27) 36 (29-42) .005
GRFS
100 d 63 (52-74) 52 (44-60) 63 (58-67) 58 (51-65) .12
6 mo 41 (30-52) 31 (24-38) 38 (34-43) 33 (26-39) .20
1 yr 24 (15-34) 14 (9-21) 16 (13-20) 11 (8-16) .10
2 yr 13 (6-22) 10 (5-15) 11 (8-14) 7 (4-11) .29
CRFS
100 d 66 (55-77) 67 (60-75) 73 (68-77) 70 (63-76) .52
6 mo 49 (37-61) 47 (40-55) 55 (50-59) 47 (41-54) .22
1 yr 37 (27-49) 35 (27-42) 37 (32-42) 31 (25-38) .50
2 yr 21 (12-32) 26 (20-34) 28 (24-33) 22 (17-28) .31
Neutrophil recovery
14 days 46 (35-58) 32 (25-40) 35 (31-40) 69 (62-75) <.001
28 days 97 (92-100) 96 (92-99) 96 (94-98) 95 (92-98) .91
Platelet recovery
14 days 17 (9-27) 19 (13-27) 19 (13-27) 18 (13-24) .61
28 days 73 (62-84) 82 (75-89) 83 (79-87) 80 (74-85) .38
*statistical significance.
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alloHCT.While some studies have compared the CNIs (TAC ver-
sus CYSP) and others have compared MTX- and MMF-contain-
ing GVHD prophylaxis, no study to date has investigated all 4
regimens concomitantly to compare the outcomes after RIC
alloHCT, and, therefore, there has been no convincing evidence
to date supporting the use of a particular regimen in the RIC
setting.
We have made several important observations in this anal-
ysis. No single GVHD prevention regimen is superior, the lim-
ited power notwithstanding, to detect differences in aGVHD
and survival outcomes in the MRD group. In those with URD,
however, MTX-TAC performed better than MMF-CYSP and
resulted in 44% risk reduction in grade II to IV and 48% risk
reduction in grade III to IV aGVHD. Furthermore, MTX-CYSP
resulted in 48% reduction in the incidence of grade II to IV
aGVHD relative to MMF-CYSP, but did not show statisticallysignificant difference in the grade III to IV aGVHD risk. All 4
regimens resulted in similar cGVHD incidence after URD
alloHCT. MTX-TAC, in addition, was associated with 32% lower
NRM risk compared with MMF-TAC. Furthermore, MTX-TAC
was associated with 88% increase in relapse risk relative to
MMF-CYSP but did not meet statistical significance when com-
pared with MMF-TAC. Higher relapse risk observed with MTX-
TAC did not translate into worse DFS and OS as the analysis
revealed no significant difference among any of the cohorts in
the URD group. No significant interaction was found between
GVHD prophylaxis and the conditioning, but patients receiving
Flu/Mel conditioning had significantly higher risk of grade II to
IV (HR, 1.75; P < .001) and grade III to IV (HR, 2.71; P < .001)
aGVHD compared with the Flu/Bu regimen (Table 6). The risks
of cGVHD and NRM with Flu/Mel conditioning were also
increased but did not meet statistical significance (P = .03 and
.05, respectively).
Table 6
Multivariate analyses in URD RIC alloHCT
n (%) Estimate (95% CI) P Value
Grade II-IV aGVHD
GVHD prophylaxis <.001*
MTX-TAC (reference) 429 (49) 1.0
MMF-CYSP 152 (17) 1.8 (1.3-2.4) <.001*
MTX-CYSP 71 (8) .8 (.5-1.2) .29
MMF-TAC 216 (25) 1.3 (1.0-1.7) .03
Conditioning regimen / ATG .002*
Bu+Flu § others (reference) 173 (20) 1.0
ATG § Bu § Flu § others 414 (48) 1.1 (.8-1.4) .61
Flu+Mel § others 147 (17) 1.7 (1.3-2.4) <.001*
TBI § Cy § Flu § others 134 (15) 1.2 (.8-1.7) .37
Disease status .01*
Early (reference) 512 (59) 1.0
Advanced 206 (24) 1.1 (.9-1.5) .25
Intermediate 127 (15) .7 (.5-1.0) .03
Missing 23 (3) 1.6 (.9-2.7) .08
Donor type
7/8-matched URD (reference) 172 (20) 1.0
8/8-matched URD 696 (80) .7 (.5-.9) .002*
Grade III-IV aGVHD
GVHD prophylaxis .01*
MTX-TAC (reference) 428 (49) 1.0
MMF-CYSP 152 (18) 1.9 (1.2-3.1) .006*
MTX-CYSP 71 (8) .8 (.4-1.6) .53
MMF-TAC 214 (257) 1.5 (1.0-2.3) .03
Conditioning regimen / ATG <.001*
Bu+Flu § others (reference) 173 (20) 1.0
ATG § Bu § Flu § others 412 (48) 1.1 (.7-1.7) .78
Flu+Mel § others 146 (17) 2.7 (1.6-4.4) <.001*
TBI § Cy § Flu § others 134 (15) .9 (.5-1.6) .66
Disease .02*
AML (reference) 495 (57) 1.0
ALL 39 (4) .4 (.1-1.2) .10
CML 48 (5) 2.1 (1.1-4.0) .03
MDS 283 (33) 1.4 (1.0-2.0) .08
Disease status .04*
Early (reference) 511 (59) 1.0
Advanced 204 (24) 1.2 (.8-1.7) .46
Intermediate 127 (15) .7 (.4-1.3) .25
Missing 23 (3) 2.3 (1.2-4.5) .01
Donor type
7/8-matched URD (reference) 172 (20) 1.0
8/8-matched URD 693 (80) .5 (.4-.7) <.001*
Chronic GVHD
GVHD prophylaxis .35
MTX-TAC (reference) 428 (49) 1.0
MMF-CYSP 152 (17) 1.3 (.9-1.7) .10
MTX-CYSP 70 (8) 1.0 (.7-1.5) .96
MMF-TAC 217 (25) 1.2 (.9-1.5) .18
Conditioning regimen / ATG <.001*
Bu+Flu § others (reference) 174 (20) 1.0
ATG § Bu § Flu § others 413 (48) .7 (.6-1.0) .03
Flu+Mel § others 146 (17) 1.4 (1.0-1.9) .03
TBI § Cy § Flu § others 134 (15) 1.4 (1.0-2.0) .04
Year of transplant .03*
2000-2004 (reference) 80 (9) 1.0
2005-2008 366 (42) .7 (.5-1.0) .03
2009-2013 421 (49) .6 (.4-.9) .007*
OS
GVHD prophylaxis .82
MTX-TAC (reference) 432 (49) 1.0
MMF-CYSP 153 (17) 1.0 (.8-1.2) .97
MTX-CYSP 71 (8) 1.1 (.8-1.5) .49
MMF-TAC 218 (25) 1.1 (.9-1.3) .47
Age at transplant .008*
18-29 yr (reference) 38 (4) 1.0
30-39 yr 54 (6) .6 (.3-1.0) .03
40-49 yr 80 (9) .8 (.5-1.3) .37
50-64 yr 444 (51) .9 (.6-1.4) .67
(continued)
65+ yr 258 (29) 1.1 (.7-1.7) .55
Disease status .004*
Early (reference) 515 (59) 1.0
Advanced 208 (24) 1.2 (1.0-1.5) .02
Intermediate 127 (14) 1.0 (.8-1.3) .82
Missing 24 (3) 2.0 (1.3-3.1) .002*
Donor type
7/8-matched URD (reference) 172 (20) 1.0
8/8-matched URD 702 (80) .7 (.6-.8) <.001*
KPS .002*
<90 (reference) 372 (43) 1.0
90-100 475 (54) .8 (.6-.9) .001*
Missing 27 (3) 1.1 (.7-1.6) .71
Sorror comorbidity index .05*
0-1 (reference) 191 (22) 1.0
2 315 (36) 1.1 (.9-1.4) .43
Missing 20 (2) .5 (.3-1.1) .09
N/A before 2007 348 (40) 1.2 (1.0-1.5) .08
DFS
GVHD prophylaxis .68
MTX-TAC (reference) 423 (49) 1.0
MMF-CYSP 153 (18) .9 (.7-1.1) .28
MTX-CYSP 67 (8) 1.0 (.7-1.4) .94
MMF-TAC 216 (25) 1.0 (.8-1.2) .82
Age at transplant .04*
18-29 yr (reference) 38 (4) 1.0
30-39 yr 52 (6) .5 (.3-.9) .02
40-49 yr 78 (9) .8 (.5-1.2) .24
50-64 yr 439 (51) .9 (.6-1.3) .59
65+ yr 252 (29) 1.0 (.6-1.4) .88
Disease status .003*
Early (reference) 511 (59) 1.0
Advanced 204 (24) 1.4 (1.1-1.6) <.001*
Intermediate 121 (14) 1.1 (.9-1.4) .46
Missing 23 (3) 1.7 (1.0-2.6) .03
Donor type
7/8-matched URD (reference) 170 (20) 1.0
8/8-matched URD 689 (80) .8 (.6-.9) .006*
KPS .005*
<90 (reference) 361 (42) 1.0
90-100 471 (55) .8 (.7-.9) .002*
Missing 27 (3) 1.1 (.7-1.6) .70
NRM
GVHD prophylaxis .05
MTX-TAC (reference) 423 (49) 1.0
MMF-CYSP 153 (18) 1.4 (1.0-1.9) .06
MTX-CYSP 67 (8) 1.3 (.8-2.0) .26
MMF-TAC 216 (25) 1.5 (1.1-2.0) .008*
Age at transplant .003*
18-29 yr (reference) 38 (4) 1.0
30-39 yr 52 (6) .6 (.3-1.3) .20
40-49 yr 78 (9) .8 (.4-1.7) .60
50-64 yr 439 (51) 1.1 (.6-2.2) .69
65+ yr 252 (29) 1.5 (.8-3.0) .20
Conditioning regimen / ATG .008*
Bu+Flu § others (reference) 172 (20) 1.0
ATG § Bu § Flu § others 410 (48) .9 (.6-1.2) .43
Flu+Mel § others 143 (17) 1.4 (1.0-2.1) .05
TBI § Cy § Flu § others 134 (16) .8 (.5-1.2) .35
Disease status .02*
Early (reference) 511 (59) 1.0
Advanced 204 (24) .9 (.7-1.2) .68
Intermediate 121 (14) .8 (.6-1.2) .34
Missing 23 (3) 2.2 (1.3-3.9) .006*
Donor type <.001*
7/8-matched URD (reference) 170 (20) 1.0
8/8-matched URD 689 (80) .5 (.4-.7) <.001*
Donor-recipient CMV match .04*
/ (reference) 215 (25) 1.0
+/+ 201 (23) 1.2 (.8-1.7) .30
+/ 80 (9) 1.7 (1.1-2.6) .01
/+ 340 (40) 1.3 (1.0-1.8) .05
Missing 23 (3) 2.2 (1.1-4.2) .02
KPS .007*
<90 (reference) 361 (42) 1.0
(continued)
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90-100 471 (55) .7 (.5-.9) .002*
Missing 27 (3) .9 (.5-1.7) .82
Relapse
GVHD prophylaxis .006*
MTX-TAC (reference) 423 (49) 1.0
MMF-CYSP 153 (18) .5 (.4-.7) <.001*
MTX-CYSP 67 (8) .8 (.5-1.2) .35
MMF-TAC 216 (25) .7 (.5-1.0) .03
Conditioning regimen / ATG .003*
Bu+Flu § others (reference) 172 (20) 1.0
ATG § Bu § Flu § others 410 (48) .8 (.6-1.1) .26
Flu+Mel § others 143 (17) .5 (.3-.7) <.001*
TBI § Cy § Flu § others 134 (16) 1.0 (.7-1.5) .99
Disease .006*
AML (reference) 492 (57) 1.0
ALL 37 (4) 1.1 (.7-1.9) .66
CML 48 (6) .6 (.3-1.1) .09
MDS 282 (33) .6 (.5-.9) .002*
Disease status <.001*
Early (reference) 511 (59) 1.0
Advanced 204 (24) 1.8 (1.4-2.3) <.001*
Intermediate 121 (14) 1.2 (.9-1.7) .17
Missing 23 (3) 1.2 (.5-2.8) .64
Sex .03
Male (reference) 487 (57) 1.0
Female 372 (43) 1.3 (1.0-1.6) .03
* statistical significance.
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of alloHCT after CYSP [21,22] or TAC [23] combined with MTX
or MMF in the myeloablative setting. One study enrolled
alloHCT from URD [21], another study from MRD [22], and a
third study included both [23]. None of the studies showed a
statistically significant difference in the cumulative incidence
of aGVHD among the regimens. Bolwell et al. [22] reported the
randomized study comparing MMF-CYSP and MTX-CYSP
(n = 40) after marrow transplantation using MRD []. No differ-
ence was observed in the incidence of GVHD or survival. Per-
kins et al. [23] reported the results of a randomized phase II
study comparing MMF-TAC and MTX-TAC after alloHCT from
MRD and URD (n = 89) []. Patients in the MMF cohort were less
likely to experience severe mucositis, and the cumulative inci-
dence of grade II to IV aGVHDwas similar. However, the cumu-
lative incidence of grade III to IV aGVHD was higher in theFigure 2. (A). Adjusted curves for cumulative incidence of aGVHD in MRD RIC alloH
CYSP-MMF, and TAC-MMF. (B) Adjusted curves for cumulative incidence of aGVHD i
TAC-MTX, CYSP-MTX, CYSP-MMF, and TAC-MMF.MMF arm (19% versus 4%; P = .03), predominantly in MAC
alloHCT using URD. A meta-analysis of the previously men-
tioned 3 randomized trials by the Cochrane Collaboration
found no differences in the rates of aGVHD and cGVHD among
the different regimens [24]. There was no evidence for a signif-
icant difference between MMF and MTX for the incidence of
aGVHD and cGVHD, neutrophil engraftment, incidence of
relapse, NRM, and OS. The results are also in accord with those
of a meta-analysis of 11 studies [2] including 1076 patients (a
mix of MAC and RIC alloHCT recipients) that determined
greater incidence of grade III to IV aGVHD in MMF recipients
(HR, 1.6; 95% CI, 1.2 to 2.3). The increased risk of severe aGVHD
with MMF was limited to the patients with URD and was not
evident after MRD alloHCT. The 3 prospective trials had rela-
tively small sample sizes and only included patients receiving
MAC and therefore, their findings cannot be applied to RIC
patients. It is noteworthy that none of the previously men-
tioned studies including the meta-analyses demonstrated any
significant differences in the relapse risk between MTX- and
MMF-based GVHD regimens, unlike reported by our study. We
can only speculate that there are unknown variables and con-
founders, in addition to the competing risk of low NRM that
contributed to the increased relapse risk and neutralized any
possible survival advantage MTX-based regimens could have
had in URD group.
Eapen et al. [16] compared outcomes between bone mar-
row and peripheral blood grafts for RIC alloHCT for patients
with AML, MDS and non-Hodgkin lymphoma using URD in 88
US transplant centers (2000 to 2008) and reported no differen-
ces in outcomes between the 2 graft sources [], but patients
receiving MMF (versus MTX) had an increased risk of grade II
to IV and III to IV aGVHD, cGVHD, NRM, and worse OS. Patients
with ALL and those receiving TBI were excluded in this study.
Despite the differences in the primary objectives and patient
populations between the 2 studies, the results of our analysis
are in concordance with Eapen et al.’s [16] study as we show
MMF-containing regimens are associated with worse interme-
diate outcomes without impact on OS in the URD setting. This
is an important study because it examines not only the efficacy
of MTX or MMF, but also the added impact of TAC and CYSP in
ensuring post-alloHCT outcomes. To compare only MTX andCT patients on 1 of the 4 GVHD prophylaxis regimens: TAC-MTX, CYSP-MTX,
n URD RIC alloHCT patients receiving 1 of the 4 GVHD prophylaxis regimens:
Figure 3. (A). Adjusted curves for OS in MRD RIC alloHCT patients receiving 1 of the 4 GVHD prophylaxis regimens: TAC-MTX, CYSP-MTX, CYSP-MMF, and TAC-MMF.
(B) Adjusted curves for OS in URD RIC alloHCT patients receiving 1 of the 4 GVHD prophylaxis regimens: TAC-MTX, CYSP-MTX, CYSP-MMF, and TAC-MMF.
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no difference in efficacy and can be used interchangeably and
the study findings do not support this assumption.
Owing to the retrospective nature, the findings of the study
need to be interpreted with caution. We acknowledge the dif-
ferences in patient, disease, and transplant characteristics
among the cohorts in both donor groups, especially the small
sample size in certain cohorts (MMF-TAC cohort in the MRD
group andMTX-CYSP in the URD group), differences in the pro-
portions of ATG recipients in the cohorts of the URD group and
the fact that the inclusion of ATG in the conditioning makes for
a heterogeneous study population. These differences were
addressed by performing a controlled analysis that accounted
for all the characteristics and any center effects. We also exam-
ined the study population for differences in the outcomes of
grade II to IV and grade III to IV aGVHD and cGVHD after
excluding ATG recipients: univariate analysis showed
cumulative incidence of grade II to IV aGVHD was highest
with MMF-CYSP and lowest with MTX-TAC in both the
MRD and URD groups (Supplementary Tables 1A and 1B),
but no significant differences in the incidence of grade III
to IV aGVHD were observed in either group. cGVHD was
observed more frequently with CYSP regimens than TAC in
the MRD group, and similarly, in the URD group, MMF-
CYSP had higher incidence of cGVHD compared with TAC-
based regimens.
Despite carefully considering multiple potentially signifi-
cant variables, the effect of unrecognized biases and residual
confounding in the analysis cannot be ruled out. For
instance, the dose of MTX and the dose and schedule of MMF
in the regimens are variable among the transplant centers.
Different dosing protocols for short-course MTX and differ-
ent doses and duration of MMF adopted by the transplant
centers were not captured in the database. It has been dem-
onstrated that higher trough levels of MMF attributed to
intensified dosing are correlated with a decreased incidence
of severe GVHD after umbilical cord blood transplantation
[25,26]. Moreover, the proportion of patients that did not
receive all 4 doses of MTX due to severe oropharyngeal
mucositis is not known. We cannot confirm that oral (and
not intravenous) formulations of TAC and CYSP were used
for all RIC alloHCT in the study. We also recognize thelimitation in having variable therapeutic target blood level
ranges for TAC and CYSP at different centers. Furthermore,
we examined the cumulative incidences of cGVHD of any
grade reported to the database and did not specifically eval-
uate the risk of moderate-to-severe or organ-specific cGVHD
in the cohorts.
It is also important to note in the study the trade-off
between low NRM and higher relapse risk with MTX-TAC com-
pared with MMF-CYSP, resulting in no difference in OS. For
this reason, it would be worth considering a future prospective
study in the URD patient population using the composite end-
point such as GVHD- and relapse-free survival (GRFS) that
assesses all significant and relevant endpoints [27]. The events
for GRFS include grade III to IV aGVHD, systemic therapy-
requiring cGVHD, relapse, or death. A similar composite end-
point that has been in vogue is cGVHD- and relapse-free sur-
vival, which includes survival without development of
cGVHD, disease relapse or progression and death [28]. Interest-
ingly, the analysis for both GRFS and cGVHD- and relapse-free
survival did not reveal any significant differences among the
MRD and URD cohorts (Tables 3 and 5).
In summary, in this observational study, we described the
outcomes after RIC alloHCT using the 4 CNI-based regimens.
This differentiates the study in that we considered the 2 drugs
of each prophylactic regimen as a unique combination, which
enabled comparisons among the 4 regimens. This analysis
demonstrated equivalent outcomes in those with MRD using
either of the 4 CNI-based combinations and inferior efficacy of
MMF-based approach with regard to grade II to IV and III to IV
aGVHD and NRM in those with URD. Moreover, the analysis
did not suggest using a particular regimen in URD alloHCT
recipients using RIC and peripheral blood graft, based on the
lack of significant differences in OS, even though aGVHD risk
was significantly improved with MTX-CNI regimens and there
may be a trend for improved 1-year GRFS in the URD group
with MTX-CNI than with MMF-CNI. Finally, a prospective ran-
domized controlled trial of URD RIC alloHCT recipients is
needed to evaluate these GVHD prophylaxis regimens with
uniform dosing schedules and target pharmacokinetic ranges
and using novel endpoints such as GRFS to confirm the find-
ings of this study. The results of such a trial may also inform
the ideal partner for GVHD prevention strategies such as
S. Chhabra et al. / Biol Blood Marrow Transplant 25 (2019) 7385 85post-transplant cyclophosphamide and other novel agents in
the future clinical trials.SUPPLEMENTARY DATA
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